Literature DB >> 3890094

Klebsiella bacteremia: an analysis of 100 episodes.

M García de la Torre, J Romero-Vivas, J Martínez-Beltrán, A Guerrero, M Meseguer, E Bouza.   

Abstract

During a five-year period, 204 patients had klebsiella bacteremia at this institution; these cases constituted 6.6% of the total episodes of bacteremia. The incidence was 2.3 cases per 1,000 admitted patients. A random group of 100 cases was chosen for analysis in the present study. The disease was community acquired in 23%, nosocomially acquired in 77%, unimicrobial in 88%, or part of a polymicrobial bacteremia in 12% of episodes. Three-quarters of the episodes were caused by Klebsiella pneumoniae and the remaining one-quarter, by Klebsiella oxytoca. Portals of entry, in decreasing order of frequency, were urinary, respiratory, and biliary tracts. Twenty-four percent of the Klebsiella isolates were resistant to gentamicin. The most frequent clinical finding (in 96% of the cases) was fever. Shock occurred in 22% and pyogenic metastatic foci, in 5% of the patients. None of the patients had evidence of disseminated intravascular coagulation. Overall mortality was 25%, and factors associated with poor prognosis were inadequacy of antimicrobial chemotherapy, septic shock, type of underlying disease, and clinical condition of the patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890094     DOI: 10.1093/clinids/7.2.143

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  23 in total

Review 1.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Bacteriological profile of neonatal septicemia.

Authors:  K Chugh; B B Aggarwal; V K Kaul; S C Arya
Journal:  Indian J Pediatr       Date:  1988 Nov-Dec       Impact factor: 1.967

3.  Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2.

Authors:  Michael A Bachman; Jennifer E Oyler; Samuel H Burns; Mélissa Caza; François Lépine; Charles M Dozois; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

4.  Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development.

Authors:  S J Cryz; P M Mortimer; V Mansfield; R Germanier
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

5.  First report of septic arthritis caused by Klebsiella oxytoca.

Authors:  Armelle Ménard; Jérome Harambat; Sabine Pereyre; Jean-Roger Pontailler; Francis Mégraud; Olivier Richer
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

6.  Analysis of complement C3 deposition and degradation on Klebsiella pneumoniae.

Authors:  S Albertí; D Alvarez; S Merino; M T Casado; F Vivanco; J M Tomás; V J Benedí
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

7.  C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins.

Authors:  S Albertí; G Marqués; S Camprubí; S Merino; J M Tomás; F Vivanco; V J Benedí
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Recommended test panel for differentiation of Klebsiella species on the basis of a trilateral interlaboratory evaluation of 18 biochemical tests.

Authors:  Dennis S Hansen; Hazel M Aucken; Titi Abiola; Rainer Podschun
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Enterobacteriaceae bacteremias among cancer patients: an observational cohort study.

Authors:  Andrés F Henao-Martínez; Guido R González-Fontal; José R Castillo-Mancilla; Ivana V Yang
Journal:  Int J Infect Dis       Date:  2013-01-10       Impact factor: 3.623

10.  Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice.

Authors:  M Trautmann; O Brückner; R Marre; H Hahn
Journal:  Infection       Date:  1988       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.